BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37897831)

  • 1. Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models.
    Yuan Y; Fan J; Liang D; Wang S; Luo X; Zhu Y; Liu N; Xiang T; Zhao X
    Transl Oncol; 2024 Jan; 39():101803. PubMed ID: 37897831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor T cells targeting cell surface GRP78 efficiently kill glioblastoma and cancer stem cells.
    Wang S; Wei W; Yuan Y; Sun B; Yang D; Liu N; Zhao X
    J Transl Med; 2023 Jul; 21(1):493. PubMed ID: 37481592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-Surface GRP78-Targeted Chimeric Antigen Receptor T Cells Eliminate Lung Cancer Tumor Xenografts.
    Wang S; Wei W; Yuan Y; Guo J; Liang D; Zhao X
    Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptor T Cells Targeting Cell Surface GRP78 to Eradicate Acute Myeloid Leukemia.
    Yu W; Zhang H; Yuan Y; Tang J; Chen X; Liu T; Zhao X
    Front Cell Dev Biol; 2022; 10():928140. PubMed ID: 35990606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
    Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
    Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer.
    Zhu H; Fang X; Tuhin IJ; Tan J; Ye J; Jia Y; Xu N; Kang L; Li M; Lou X; Zhou JE; Wang Y; Yan Z; Yu L
    J Cancer Res Clin Oncol; 2022 Sep; 148(9):2261-2274. PubMed ID: 35445870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy.
    Zhang E; Yang P; Gu J; Wu H; Chi X; Liu C; Wang Y; Xue J; Qi W; Sun Q; Zhang S; Hu J; Xu H
    J Hematol Oncol; 2018 Aug; 11(1):102. PubMed ID: 30103775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
    PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.
    Arnoletti JP; Buchsbaum DJ; Huang ZQ; Hawkins AE; Khazaeli MB; Kraus MH; Vickers SM
    J Gastrointest Surg; 2004 Dec; 8(8):960-9; discussion 969-70. PubMed ID: 15585383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo.
    Chen YH; Chen YC; Lin CC; Hsieh YP; Hsu CS; Hsieh MC
    Cancer Manag Res; 2020; 12():4645-4665. PubMed ID: 32606957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer.
    Chen W; Li M; Younis MH; Barnhart TE; Jiang D; Sun T; Lang JM; Engle JW; Zhou M; Cai W
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):861-870. PubMed ID: 34519889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
    Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel CAR-T cells targeting TRKB for the treatment of solid cancer.
    Liang D; Tang J; Sun B; He S; Yang D; Ma H; Yun Y; Zhu Y; Wei W; Chen H; Zhao X
    Apoptosis; 2024 Mar; ():. PubMed ID: 38498249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
    Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
    Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
    Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
    DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
    J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid.
    Balasubramanian S; Chandraratna RA; Eckert RL
    Carcinogenesis; 2004 Aug; 25(8):1377-85. PubMed ID: 14976133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression.
    Bharadwaj U; Marin-Muller C; Li M; Chen C; Yao Q
    Mol Cancer; 2011 Aug; 10():106. PubMed ID: 21880146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.